FDA says use of popular GLP-1 drugs may lead to a rare but very serious, side effect
The Food and Drug Administration said the highly popular GLP-1 drugs will now carry a new warning on their labels after several reports of vision loss among users. Regulators announced on Monday that makers of all GLP-1 weight-loss drugs, including Novo Nordisk’s Ozempic and Wegovy, will have to add information to the drugs’ “warnings and precautions” labels after reports of a side effect that ...